Page last updated: 2024-12-06

gusperimus

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gusperimus: synthesized by chemical modification of spergualin; in combination with cyclosporin A prevents diabetes in predisposed NOD mice; structure given in first source; RN given refers to (-)-isomer trihydrochloride [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID55362
CHEMBL ID406117
CHEBI ID135609
SCHEMBL ID28026
MeSH IDM0112890

Synonyms (37)

Synonym
NCI60_003229
gusperimus
deoxyspergualin
n-[2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxo-ethyl]-7-guanidino-heptanamide
(+-)-15-deoxyspergualin
heptanamide, 7-(aminoiminomethyl)amino-n-2-[4-(3-aminopropylamino-butyl)amino)]-1-hydroxy-2-oxoethyl-
heptanamide, 7-((aminoiminomethyl)amino)-n-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-
CHEBI:135609
CHEMBL406117
gusperimus (inn)
D08032
104317-84-2
n-[2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide
uj0zj76do9 ,
unii-uj0zj76do9
gusperimus [inn]
FT-0631032
98629-43-7
gusperimus [who-dd]
(+/-)-15-deoxyspergualin
(+/-)-deoxyspergualin
(+/-)-n-(((4-((3-aminopropyl)amino)butyl)carbamoyl)hydroxymethyl)-7-guanidinoheptanamide
gusperimus [mi]
SCHEMBL28026
n-[4-(3-aminopropyl)aminobutyl]-2-(7-guanidinoheptanamido)-2-hydroxyethanamide
7-([amino(imino)methyl]amino)-n-[2-((4-[(3-aminopropyl)amino]butyl)amino)-1-hydroxy-2-oxoethyl]heptanamide #
DB12692
n-(2-(4-(3-aminopropylamino)butylamino)-1-hydroxy-2-oxoethyl)-7-guanidinoheptanamide
DTXSID60861078
n-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-7-guanidinoheptanamide
Q10910504
(+/-)-15-deoxyspergualin; (+/-)-deoxyspergualin;
FT-0776026
()-15-deoxyspergualin; ()-deoxyspergualin;
heptanamide, 7-[(aminoiminomethyl)amino]-n-[2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]-
n-[4-(3-aminopropylamino)butylcarbamoyl-hydroxy-methyl]-7-(diaminomethylideneamino)heptanamide
AKOS040751975

Research Excerpts

Overview

Gusperimus is an anti-inflammatory drug that has shown to be effective in managing autoimmunity and preventing graft rejection. It is a relatively safe immunosuppressive drug with low cytotoxicity and reversible side effects.

ExcerptReferenceRelevance
"Gusperimus is an anti-inflammatory drug that has shown to be effective in managing autoimmunity and preventing graft rejection. "(
de Haan, BJ; de Vos, P; Faas, MM; López, BL; Navarro Chica, CE; Qin, T; Sierra, L; Smink, AM, 2021
)
2.06
"Gusperimus is a relatively safe immunosuppressive drug with low cytotoxicity and reversible side effects."( Design and characterization of Squalene-Gusperimus nanoparticles for modulation of innate immunity.
de Haan, BJ; de Vos, P; Faas, MM; López, BL; Navarro Chica, CE; Sierra, L; Smink, AM, 2020
)
1.55
"Gusperimus is an immunosuppressive drug with a unique mode of action. "( Gusperimus: immunological mechanism and clinical applications.
Floßmann, O; Jayne, DR; Perenyei, M, 2014
)
3.29

Toxicity

ExcerptReferenceRelevance
" The adverse effect of DSG was partly reversed by the simultaneous administration of granulocyte colony-stimulating factor (G-CSF) and/or erythropoietin (EPO), suggesting the need for the administration of these cytokines in the case of bone marrow transplants treated with DSG."( In vivo effects of the immunosuppressant 15-deoxyspergualin on hematopoiesis in murine allogeneic bone marrow chimeras. Its thrombopoietic activity and reversal of adverse effects with granulocyte colony-stimulating factor and/or erythropoietin.
Fujii, Y; Han, M; Hashino, S; Imai, K; Imamura, M; Kobayashi, H; Kobayashi, M; Kobayashi, S; Tanaka, J; Zhu, X, 1994
)
0.29
" However, DSG has severe adverse effects that limits its use."( Chronopharmacology for deoxyspergualin: toxicity and efficacy in the rat.
Fujimura, A; Hashizume, K; Kawarasaki, H; Kobayashi, E; Matsuda, K; Mizuta, K; Sugimoto, K; Uchida, H, 1999
)
0.3
" The most common adverse reaction was reversible neutropenia."( Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy.
Hotta, O; Imai, H; Kobayashi, M; Konta, T; Miyazaki, M; Nose, M; Shiiki, H; Suzuki, S; Tomida, C; Tsubakihara, Y; Yamauchi, A; Yokoyama, H; Yoshimura, M, 2006
)
0.33

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies were completed on 26 patients ranging from doses of 80 to 2792 mg/m2."( Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study.
Boldt, DH; Brown, TD; Cagnola, J; Craig, JB; Harman, G; Havlin, KA; Koeller, J; Kuhn, JG; Phillips, J; Weiss, GR, 1995
)
0.29
" The mean Cmax was 4117 ng/ml (range 1944-7166 ng/ml) and the mean AUC 12505 ng."( Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection.
Lindholm, A; Ohlman, S; Schindel, F; Zilg, H, 1994
)
0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
" Therefore, the drug-sensitive cycling population of the tumor cells was reduced, and combination with other antitumor agents was antagonistic, if they were administered simultaneously or consecutively with NKT-01."( The nature of in vivo cell-killing of deoxyspergualin, and its implication in combination with other antitumor agents.
Nishikawa, K; Shibasaki, C; Takahashi, K; Takeuchi, T; Uchida, T, 1991
)
0.28
"The effects of 15-deoxyspergualin (DSG) alone and in combination with FK 506 (FK) on liver regeneration after 2/3 hepatectomy was studied."( Enhanced liver regeneration in rats treated with 15-deoxyspergualin alone and in combination with FK 506.
Aono, T; Koyama, S; Muto, T; Ohtake, M; Okamura, N; Sakaguchi, T; Tsukada, K; Yoshida, K, 1993
)
0.29
"The present study aimed to evaluate the effect of plasma exchange (PE) in combination with certain immunosuppressive agents on the survival of guinea-pig hearts in C6-deficient (C6-) rats."( Effect of plasma exchange in combination with deoxyspergualin on the survival of guinea-pig hearts in macrophage-depleted C6-deficient rats.
Korsgren, O; Sun, S; Tibell, A; Van Rooijen, N; Wu, G, 2003
)
0.32
" These results clearly demonstrated that the oxygen free radical plays a toxic role in cardiac allografts with ongoing rejection and, therefore, the administration of h-SOD in combination with DSG can minimize the graft injury."( Rescue therapy for acute rejection using 15-deoxyspergualin (DSG) in combination with superoxide dismutase (SOD) on cardiac allografts in rats.
Amemiya, H; Hayashi, R; Kanashiro, M; Suzuki, S, 1992
)
0.28
"In an MHC class I-disparate combination of mouse strains, a single intravenous injection of donor spleen cells combined with 10 suboptimal doses of 15-deoxyspergualin (DSG) administration was effective in inducing donor-specific suppression of cytotoxic T-lymphocyte (CTL) responses and prolonged survival of the relevant skin allograft."( Both T and non-T cells with proliferating potentials are effective in inducing suppression of allograft responses by alloantigen-specific intravenous presensitization combined with suboptimal doses of 15-deoxyspergualin.
Iwanami, N; Kurita, T; Matsumura, H; Matsuura, T; Miyazawa, M; Tabata, N; Tahara, H,
)
0.13
" T-cell depletion combined with a brief course of deoxyspergualin (DSG), a drug with inhibitory effects on monocytes and macrophages, induces tolerance in nonhuman primates."( Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin.
Cendales, LK; Chamberlain, C; Elster, EA; Hale, DA; Hoffmann, SC; Kampen, RL; Kirk, AD; Kleiner, DE; Mannon, RB; Swanson, JS; Wakefield, T, 2005
)
0.33

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of mycophenolic acid, the active metabolite of mycophenolate mofetil, has been reported to be reduced by aluminium/magnesium hydroxide-containing antacids and cholestyramine."( Clinically significant drug interactions with new immunosuppressive agents.
Mignat, C, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Plasmapheresis was performed for 6 and 9 days, respectively, and DSG was given for 5 days in a dosage of 6 mg/kg body weight per day."( Rejection associated with early appearance of donor-reactive antibodies after kidney transplantation treated with plasmapheresis and administration of 15-deoxyspergualin. A report of two cases.
Gannedahl, G; Groth, CG; Gudmundsson, S; Larsson, E; Ohlman, S; Persson, U; Tötterman, TH; Tydén, G; Weiss, L; Wikström, B, 1992
)
0.28
"5-50 mg/kg according to the same dosing protocol."( Therapeutic activity of deoxyspergualin in comparison with cyclosporin A, and its combined use with cyclosporin A and prednisolone in highly allogeneic skin transplantation in the rat.
Abe, F; Fujii, A; Hayashi, M; Mae, T; Nemoto, K; Sugawara, Y; Takeuchi, T, 1992
)
0.28
" We performed the administration of DSG in fifteen patients, who had rejection episodes, with a dosage of 3 mg/kg/day or 5 mg/kg/day for five days by drip infusion."( [The experience of administration of 15-deoxyspergualin on rejection in kidney transplant recipients].
Ishibashi, M; Jiang, H; Kameoka, H; Kokado, Y; Okuyama, A; Sonoda, T; Takahara, S; Takano, Y, 1992
)
0.28
" A dose-response study showed that FK506 suppressed EAU induction at doses 10-30 times lower CsA when given on days 0-14 postimmunization, while 15-DSG suppressed the disease development at doses very similar to CsA."( Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat.
Kawashima, H; Mochizuki, M, 1990
)
0.28
" The dosing interval seemed not to be a dominant factor regarding the activity of NKT-01."( Treatment schedule dependency of antitumor effect of deoxyspergualin.
Nishikawa, K; Shibasaki, C; Takahashi, K; Takeuchi, T, 1991
)
0.28
" A low dosage of FK 506 starting on day 0, in combination with DSG starting on day 0 or day 4 (but not on day 7), had a synergistic effect in prolonging allograft survival for 14."( The superior effect of the combination of FK 506 and deoxyspergualin on rat cardiac allograft survival.
Ishibashi, M; Jiang, H; Li, D; Namiki, M; Okuyama, A; Sonoda, T; Takahara, S, 1994
)
0.29
" Further in vivo immunologic studies should be pursued while the agent is studied in fixed dosage phase II clinical trials."( Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study.
Boldt, DH; Brown, TD; Cagnola, J; Craig, JB; Harman, G; Havlin, KA; Koeller, J; Kuhn, JG; Phillips, J; Weiss, GR, 1995
)
0.29
" A dose-response study of the number of islets required to ameliorate diabetes showed that 150 isologous islets per recipient resulted in a 75% incidence of cure at a mean of 39."( Effect of 15-deoxyspergualin on immediate function and long-term survival of transplanted islets in murine recipients of a marginal islet mass.
Farney, AC; Field, MJ; Gores, PF; Gruber, SA; Kaufman, DB; Stephanian, E; Sutherland, DE, 1994
)
0.29
" intraperitoneally) until day 28 after transplantation in a special dosage schedule, 10 out of 15 animals were normoglycaemic one week after transplantation and 6 were still normoglycaemic after ten weeks."( 15-Deoxyspergualin prolongs pancreatic islet allo- and xenograft survival in mice.
Andersson, A; Groth, CG; Korsgren, O; Sandberg, JO, 1993
)
0.29
"First, a dosing time-dependent difference in the toxicity and efficacy of DSG was determined using a heterotopic heart transplantation model."( Chronopharmacology for deoxyspergualin: toxicity and efficacy in the rat.
Fujimura, A; Hashizume, K; Kawarasaki, H; Kobayashi, E; Matsuda, K; Mizuta, K; Sugimoto, K; Uchida, H, 1999
)
0.3
"The toxicity of DSG varied with the dosing time, whereas its efficacy did not."( Chronopharmacology for deoxyspergualin: toxicity and efficacy in the rat.
Fujimura, A; Hashizume, K; Kawarasaki, H; Kobayashi, E; Matsuda, K; Mizuta, K; Sugimoto, K; Uchida, H, 1999
)
0.3
" Drug efficacy and potency was calculated based on dose-response curves of the drug-mediated decrease in CD4(+)/CD8alpha(+)/CD25(+) cells."( Coexpression of CD4 and CD8alpha on rat T-cells in whole blood: a sensitive marker for monitoring T-cell immunosuppressive drugs.
Diaz-Romero, J; Vogt, G; Weckbecker, G, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acyl-amino acidA carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID361019Inhibition of putrescine transporter-mediated [3H]putrescine transport in Plasmodium falciparum FCK2 infected human red blood cells2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID361253Growth inhibition of Plasmodium falciparum FCK2 as apicoplast copy numbers at 1 uM in [3H]hypoxanthine uptake2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID361021Antimalarial activity against Plasmodium falciparum FCK2 infected human erythrocytes with exogenous spermidine2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID361249Antimalarial activity against Plasmodium falciparum FCK2 by [3H]hypoxanthine uptake2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID361263Antimalarial activity as reduced parasitaemia after 12 hrs against Plasmodium falciparum FCK2 second asexual cycle at 1 uM by [3H]hypoxanthine uptake2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID361261Inhibition of fatty acid synthesis in Plasmodium falciparum FCK2 shizonts at 1 uM2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID186899Compound (6 mg/kg) is evaluated for prevention of graft rejection after heart allotransplantation in the Dark Agouti to Lewis rat combination.1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1. Structural modifications of the hydroxyglycine moiety.
AID361258Inhibition of fatty acid synthesis in Plasmodium falciparum FCK2 ring stage at 1 uM2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID361256TufA expression level in Plasmodium falciparum FCK2 first asexual cycle2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID134269The compound was tested in vivo against heart transplanted rat for survival (mean) after daily administration of 6 mg/kg(ip) for 10 days.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2. Structural modifications of the spermidine moiety.
AID322401Binding affinity to Hsp702008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Pyrimidinone-peptoid hybrid molecules with distinct effects on molecular chaperone function and cell proliferation.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID134267In vivo immunosuppressive activity at a dose of 1 mg/kg in mouse GVHD (graft-versus-host disease) model and the mean survival days evaluated.1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1. Structural modifications of the hydroxyglycine moiety.
AID361251Inhibition of spermidine transporter-mediated [3H]spermidine transport in human red blood cells2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID361252Inhibition of spermidine transporter-mediated [3H]spermidine transport in Plasmodium falciparum FCK2 infected human red blood cells at 1 mM2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID101790Inhibition of [3H]spermidine transport into MDA-MB-231 (human breast cancer) cells.2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Amino acid/spermine conjugates: polyamine amides as potent spermidine uptake inhibitors.
AID361260Inhibition of fatty acid synthesis in late trophozoite Plasmodium falciparum FCK2 at 1 uM2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1727032Immunosuppressive activity in B6D2F1 mouse model of graft-versus-host disease assessed as mean survival days at 1 mg/kg, ip administered for day 1 to day 10 (day 6 omitted) and measured at day 602020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID322402Binding affinity to Hsp902008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Pyrimidinone-peptoid hybrid molecules with distinct effects on molecular chaperone function and cell proliferation.
AID361250Inhibition of protein synthesis in Plasmodium falciparum FCK2 by [35S]methionine uptake2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID361020Inhibition of putrescine transporter-mediated [3H]putrescine transport in human red blood cells2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID361255Decreased processed NEAT protein FabG level in Plasmodium falciparum FCK2 first asexual cycle2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID1727033Immunosuppressive activity in Lewis rat model of Heart Allotransplantation assessed as mean survival days at 6 mg/kg, ip administered for 10 days by Manntel-Haenszel test2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID1727031Immunosuppressive activity in B6D2F1 mouse model of graft-versus-host disease assessed as mean survival days at 3 mg/kg, ip administered for day 1 to day 10 (day 6 omitted) and measured at day 602020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID361257Actin expression level in Plasmodium falciparum FCK22007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID361259Inhibition of fatty acid synthesis in Plasmodium falciparum FCK2 trophozoites at 1 uM2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum.
AID134268In vivo immunosuppressive activity in mouse GVHD (graft-versus-host disease) model and the mean survival days evaluated (dose of 3 mg/kg)1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1. Structural modifications of the hydroxyglycine moiety.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (582)

TimeframeStudies, This Drug (%)All Drugs %
pre-199083 (14.26)18.7374
1990's394 (67.70)18.2507
2000's87 (14.95)29.6817
2010's14 (2.41)24.3611
2020's4 (0.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.93 (24.57)
Research Supply Index6.49 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials40 (6.50%)5.53%
Reviews48 (7.80%)6.00%
Case Studies17 (2.76%)4.05%
Observational1 (0.16%)0.25%
Other509 (82.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (CIT-03) [NCT00434850]Phase 214 participants (Actual)Interventional2006-10-31Completed
Pilot Study of Cycling Treatment of Deoxyspergualin in Biopsy-proven Chronic Rejection of Kidney Transplantation [NCT01052259]35 participants (Actual)Interventional2009-06-30Terminated(stopped due to Insufficient patient enrollment)
Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis [NCT00530075]Phase 245 participants (Actual)Interventional2003-12-31Completed
Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus Versus Conventional Therapy in Relapse of Granulomatosis With Polyangiitis (Wegener's Granulomatosis) SPARROW Study - SPAnidin in Rel [NCT01446211]Phase 34 participants (Actual)Interventional2011-11-30Terminated(stopped due to Change of design consideration)
Safety and Efficacy Study on Deoxyspergualin (NKT-01) in Patients With Uncontrolled Lupus Nephritis Receiving Oral Corticosteroids and Prior Treatment of Standard Immunosuppressive Therapy [NCT00709722]Phase 1/Phase 221 participants (Actual)Interventional2003-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00530075 (8) [back to overview]Duration of Clinical Response
NCT00530075 (8) [back to overview]Remission of Vasculitis
NCT00530075 (8) [back to overview]ANCA
NCT00530075 (8) [back to overview]Creatinine
NCT00530075 (8) [back to overview]CRP
NCT00530075 (8) [back to overview]Haematuria
NCT00530075 (8) [back to overview]SF-36
NCT00530075 (8) [back to overview]Vasculitis Damage Index (VDI)
NCT00709722 (3) [back to overview]Complete and Partial Response Rate
NCT00709722 (3) [back to overview]SELENA-SLEDAI Score
NCT00709722 (3) [back to overview]Treatment Days With Corticosteroids of <= 7.5 mg/Day

Duration of Clinical Response

Time from Complete Remission or Partial Remission to Relapse. (NCT00530075)
Timeframe: At Entry (Day 1 of Cycle 1), Day 22 of cycles 1-6, up to 24 weeks, End of treatment period, and 3 and 6 months of follow-up period

InterventionDays (Median)
Gusperimus170

[back to top]

Remission of Vasculitis

"The primary efficacy outcome measure was remission of vasculitis. Complete remission was defined as a Birmingham vasculitis activity score (BVAS) of 0 sustained for at least 2 months. Partial remission was defined as a reduction in BVAS of 50% or more, sustained for at least 2 months, when compared with the BVAS at entry.~Entry required active Wegener's granulomatosis with a BVAS >= 4. Their disease had to be active, as measured with BVAS in which clinical manifestations caused by active vasculitis are scored on a list of predefined organ-specific items." (NCT00530075)
Timeframe: At Entry (Day 1 of Cycle 1), Day 22 of cycles 1-6, up to 24 weeks

InterventionPercentage of participants (Number)
Gusperimus95

[back to top]

ANCA

"Assessment of anti-neutrophil cytoplasmic antibody (ANCA): Number of ANCA-positive patients was counted.~ANCA are highly associatred with active WG, with c-ANCA titres observed in 90% of WG. In addition to their diagnostic value, it has been suggested that ANCA may have a predictive value for relapse in patients with systemic vasculitis." (NCT00530075)
Timeframe: At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks

InterventionNumber of participants (Number)
At EntryEnd of treatment period
Gusperimus3934

[back to top]

Creatinine

Assessment of anti-inflammatory activity of gusperimus using surrogate marker: serum creatinine level (NCT00530075)
Timeframe: At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks

Interventionmicromol/L (Median)
At EntryEnd of treatment period
Gusperimus130132

[back to top]

CRP

Assessment of anti-inflammatory activity of gusperimus using surrogate marker: serum C-reactive protein level. (NCT00530075)
Timeframe: At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks

Interventionmg/dL (Median)
At EntryEnd of treatment period
Gusperimus17.59

[back to top]

Haematuria

Assessment of anti-inflammatory activity of gusperimus using surrogate marker: number of hematuria-positive patients. (NCT00530075)
Timeframe: At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks

InterventionNumber of participants (Number)
At EntryEnd of treatment period
Gusperimus166

[back to top]

SF-36

Assessment of the impact of gusperimus on general health using the Short form-36 (SF-36) questionaire. The SF-36 is a self-report, 36 item survey measuring health-related quality-of-life. Thirty-five items are used to construct 8 scales: (1) physical functioning, (2) role physical, (3) bodily pain, (4) general health, (5) vitality, (6) social function, (7) role emotional, and (8) mental health. Raw scores are calculated as the sum of re-coded scale items and transformed to a 0 to 100 scale. If scores for all 8 scales are available, two summary measures known as component scores are derived: the Physical Health Component Score (PCS) and the Mental Health Component Score (MCS). First each scale standardized to the relevant population. Then PCS and MCS are calculated as the weighted sum of standardized scores. All scales and the component scores are positively scored so that higher scores represent better health-related quality-of-life. (NCT00530075)
Timeframe: At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks

InterventionScore on a scale (Median)
Physical component score (at Entry)Physical component score (at End of treatment periMental component score (at Entry)Mental component score (at End of treatment period
Gusperimus29.634.349.448

[back to top]

Vasculitis Damage Index (VDI)

Assessment of the degree of irreversible damage due to the vasculitis using VDI scoring system. The VDI comprises 64 items of damage (grouped into 11 organ-based systems). Total VDI score is 0 - 64. The higher scores represent the more severe damage occurred in patients. The VDI score can either increase or remain the same over time. (NCT00530075)
Timeframe: At Entry (Day 1 of Cycle 1), End of treatment period, up to 24 weeks, 6 months of follow-up period

InterventionScore on a scale (Median)
At EntryEnd of treatment period6 months of follow-up period
Gusperimus4.555

[back to top]

Complete and Partial Response Rate

A four-point scale was defined: complete response (CR), partial response (PR), stable disease (SD) or treatment failure (TF). The response criteria were defined prior to the start of the study: for a CR, PR or SD prednisone had to be decreased to <= 7.5 mg/day, a higher dosage was automatically classified as TF. The presence of urinary erythrocyte or granular casts excluded CR. As the baseline activity of every patient is different, it was necessary to define baseline proteinuria (g/24 h) or kidney function (estimated glomerular filtration rate) as the reference value for the definition of response for every patient individually. The baseline was defined as the renal function and proteinuria level before the onset of the recent LN flare which qualified the patient for the study. Response was determined as the ratio of the proteinuria or kidney function at cycle 4, 6 or 9 to the baseline values of the individual patient. (NCT00709722)
Timeframe: Screening, Day 14 of Cycles 4, 6 and 9, up to 27 weeks

InterventionPercentage of participants (Number)
Deoxyspergualin55

[back to top]

SELENA-SLEDAI Score

"The Safety of Estrogen in Lupus Erythematosus National Assessment - systemic lupus erythematosus disease activity index' (SELENA-SLEDAI) document the current activity of SLE/LN. It contains 24 items (descriptors), which are differently weighed. The score has a total range of 0 - 105. As a maximum 105 score points can be reached meaning the worst disease activity." (NCT00709722)
Timeframe: Screening, the last day of Cycles 4, 6 and 9, up to 27 weeks

InterventionScore on a scale (Mean)
ScreeningThe last day of Cycle 4The last day of Cycle 6The last day of Cycle 9
Deoxyspergualin16.912.913.711.7

[back to top]

Treatment Days With Corticosteroids of <= 7.5 mg/Day

"Entry to the study was permitted for patients with doses of oral corticosteroids (OCS) of <= 1.0 mg/kg/day (maximum dose 80 mg/day).~OCS dosage was maintained, decreased or increased according to the response to DSG.~The number of days on which the OCS dose was <= 7.5 mg/day was counted in each cycle." (NCT00709722)
Timeframe: 1st and 9th Cycle

InterventionDays (Mean)
1st Cycle9th Cyvle
Deoxyspergualin2.818

[back to top]